{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:15:50Z","timestamp":1794363350147,"version":"4.9.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Axicabtagene ciloleucel (axi\u2010cel) is an autologous anti\u2010CD19 chimeric antigen receptor (CAR) T\u2010cell therapy approved for relapsed or refractory large B\u2010cell lymphoma (R\/R LBCL). To reduce axi\u2010cel\u2013related toxicity, several exploratory safety management cohorts were added to ZUMA\u20101 (NCT02348216), the pivotal phase 1\/2 study of axi\u2010cel in refractory LBCL. Cohort 4 evaluated the rates and severity of cytokine release syndrome (CRS) and neurologic events (NEs) with earlier corticosteroid and tocilizumab use. Primary endpoints were incidence and severity of CRS and NEs. Patients received 2\u00a0\u00d7\u00a010<jats:sup>6<\/jats:sup> anti\u2010CD19 CAR T cells\/kg after conditioning chemotherapy. Forty\u2010one patients received axi\u2010cel. Incidences of any\u2010grade CRS and NEs were 93% and 61%, respectively (grade \u2265\u00a03, 2% and 17%). There was no grade 4 or 5 CRS or NE. Despite earlier dosing, the cumulative cortisone\u2010equivalent corticosteroid dose in patients requiring corticosteroid therapy was lower than that reported in the pivotal ZUMA\u20101 cohorts. With a median follow\u2010up of 14\u00b78\u00a0months, objective and complete response rates were 73% and 51%, respectively, and 51% of treated patients were in ongoing response. Earlier and measured use of corticosteroids and\/or tocilizumab has the potential to reduce the incidence of grade \u2265\u00a03 CRS and NEs in patients with R\/R LBCL receiving axi\u2010cel.<\/jats:p>","DOI":"10.1111\/bjh.17673","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T06:31:40Z","timestamp":1632983500000},"page":"388-398","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B\u2010cell lymphoma"],"prefix":"10.1111","volume":"195","author":[{"given":"Max S.","family":"Topp","sequence":"first","affiliation":[{"name":"Medizinische Klinik und Poliklinik II Universit\u00e4tsklinikum W\u00fcrzburg W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van Meerten","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen Groningen The Netherlands"},{"name":"On Behalf of HOVON\/LLPC (Lunenburg Lymphoma Phase I\/II Consortium)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"CHU Rennes University of Rennes Inserm &amp; EFS Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[{"name":"On Behalf of HOVON\/LLPC (Lunenburg Lymphoma Phase I\/II Consortium)"},{"name":"University Medical Center Utrecht Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service d\u2019He\u0301matologie et The\u0301rapie Cellulaire Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6735-8651","authenticated-orcid":false,"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[{"name":"On Behalf of HOVON\/LLPC (Lunenburg Lymphoma Phase I\/II Consortium)"},{"name":"Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Universite\u0301 de Paris, AP\u2010HP, H\u00f4pital Saint Louis, Hemato\u2010Oncology, DMU HI, Research Unit NF\u2010kappaB, Diffe\u0301renciation et Cancer Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wermke","sequence":"additional","affiliation":[{"name":"NCT\/UCC Early Clinical Trial Unit University Hospital Carl Gustav Carus Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Song","sequence":"additional","affiliation":[{"name":"The University of British Columbia Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[{"name":"Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-320X","authenticated-orcid":false,"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University of Toronto Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-9472","authenticated-orcid":false,"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[{"name":"University Hospital Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saran","family":"Vardhanabhuti","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Dong","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bot","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Plaks","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Sherman","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kerber","sequence":"additional","affiliation":[{"name":"Kite, A Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"On Behalf of HOVON\/LLPC (Lunenburg Lymphoma Phase I\/II Consortium)"},{"name":"Amsterdam UMC University of Amsterdam Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"YESCARTA\u00ae(axicbatagene ciloleucel) Summary of product characteristics. Kite Pharma EU B.V.; 2021."},{"key":"e_1_2_10_3_1","unstructured":"YESCARTA\u00ae(axicabtagene ciloleucel) Prescribing information.Kite Pharma Inc;2021."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"issue":"1","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-134362","article-title":"Long\u2010term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi\u2010cel)","volume":"136","author":"Jacobson C","year":"2020","journal-title":"Blood"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0058-4"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0094-0"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238691"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134612"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"e_1_2_10_12_1","unstructured":"ACTEMRA (tocilizumab) [package insert].South San Francisco CA:Genentech Inc;2018."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0737-3"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.022"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001900"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_10_21_1","unstructured":"U.S. Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010. National Institutes of Health National Cancer Institute."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3150"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-985X.2007.00527.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126081"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.12.10"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00592"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008865"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7567"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117199"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001463"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0280-y"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17673","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17673","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T06:59:33Z","timestamp":1692860373000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/bjh.17673"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17673","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"2021-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}